These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12769806)

  • 1. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
    Burke WJ
    Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
    Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
    Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
    Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
    Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
    Li SW; Lin TS; Minteer S; Burke WJ
    Brain Res Mol Brain Res; 2001 Sep; 93(1):1-7. PubMed ID: 11532332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
    Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
    Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
    J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.
    Panneton WM; Kumar VB; Gan Q; Burke WJ; Galvin JE
    PLoS One; 2010 Dec; 5(12):e15251. PubMed ID: 21179455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
    J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Kristal BS; Conway AD; Brown AM; Jain JC; Ulluci PA; Li SW; Burke WJ
    Free Radic Biol Med; 2001 Apr; 30(8):924-31. PubMed ID: 11295535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
    Rees JN; Florang VR; Anderson DG; Doorn JA
    Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
    Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
    Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
    Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
    Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
    J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)].
    Bonnet JJ; Legros H; Janin F; Dourmap N; Costentin J
    Ann Pharm Fr; 2004 Sep; 62(5):323-31. PubMed ID: 15314580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
    J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
    Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
    Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.
    Mexas LM; Florang VR; Doorn JA
    Neurotoxicology; 2011 Aug; 32(4):471-7. PubMed ID: 21514317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
    Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
    Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.